IPSC
NASDAQ
$2.24
Century Therapeutics Inc (IPSC)
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging its pioneering induced pluripotent stem cell (iPSC) technology, Century is committed to developing innovative off-the-shelf therapeutics designed to improve patient outcomes and expand accessibility to care. With a diverse array of clinical-stage assets and strategic collaborations that enhance its market position, Century Therapeutics presents compelling investment opportunities in the burgeoning cell therapy landscape, positioning itself for significant growth within the biotech industry.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $4.75 (+112.05%)
Market Cap
$391M
Profit Margin
70.1%
Free Cash Flow Yield
-24.50%
Beta (5Y)
1.58
Price Chart
Valuation
Market Cap$391M
P/S3.72
P/B1.45
Profitability
Gross Profit (TTM)-$86M
EBITDA-$102M
Profit Margin70.1%
Operating Margin68%
EPS-$0.52
Financial Health
Free Cash Flow Yield-24.50%
Growth & Risk
EPS 5Y CAGR-16.95%
Beta (5Y)1.58
Sharpe Ratio1.78